|  |
| --- |
| **Preferred Regimens** |
| *Two-NRTI Backbones* |
| ABC/3TC\*  |
| TDF/FTC or TDF/3TC† |
| *INSTI Regimens* |
| DTG/ABC/3TC or DTG plus a preferred 2-NRTI backbone (after the first trimester)‡  |
| RAL plus a preferred 2-NRTI backbone |
| *PI Regimens* |
| ATV/r plus a preferred 2-NRTI backbone |
| DRV/r plus a preferred 2-NRTI backbone |
| **Alternative Regimens** |
| *2-NRTI Backbones* |
| ZDV/3TC§  |
| *PI Regimens* |
| LPV/r plus a preferred 2-NRTI backbone |
| *NNRTI Regimens* |
| EFV/TDF/FTC or EFV/TDF/3TC or EFV plus a preferred 2-NRTI backboneǁ  |
| RPV/TDF/FTC or RPV plus a preferred 2-NRTI backbone¶ |

\*ABC should not be used in patients who test positive for the HLA-B\*5701 gene because of the risk of a hypersensitivity reaction.

† TDF has potential renal toxicity; thus, TDF-based dual-NRTI combinations should be used with caution in patients with renal insufficiency.

‡ Should not be initiated during the first trimester because of concerns about a possible increased risk of neural tube defects.

§ Increased potential for hematologic and other toxicities.

ǁ Birth defects have been seen in primate studies of EFV, but there has been no evidence of an increased risk of birth defects in human studies and extensive experience in pregnancy; higher rate of adverse events than for other preferred drugs.

¶ RPV is not recommended in patients with pretreatment HIV RNA >100,000 copies/mL or CD4 cell counts <200 cells/mm3; do not use with PPIs.

**Source:** U.S. Department of Health and Human Services. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Version December 7, 2018. <https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0> Accessed on 4/8/19.

**Abbreviations:** 3TC=lamivudine; ABC=abacavir; ATV/r=atazanavir/ritonavir; CD4=CD4 T lymphocyte cell; DRV/r=darunavir/ritonavir; DTG=dolutegravir; EFV=efavirenz; FTC=emtricitabine; INSTI=integrase strand transfer inhibitor; LPV/r=lopinavir/ritonavir; NNRTI=nonnucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase inhibitor; PI=protease inhibitor; PPI=proton pump inhibitor; RAL=raltegravir; RNA=ribonucleic acid; RPV=rilpivirine; TDF=tenofovir disoproxil fumarate; ZDV=zidovudine.